Covid-19
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
CDC now calls coronavirus Delta variant a ‘variant of concern’.
17 Jun, 2021 | 09:53h | UTCCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Guidance: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Commentary on Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.
17 Jun, 2021 | 09:49h | UTCCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1405276204526039041
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.
16 Jun, 2021 | 08:31h | UTCAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Original report: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Commentary on Twitter (thread – click for more)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Cardio-pulmonary sequelae in recovered COVID-19 patients: considerations for primary care.
16 Jun, 2021 | 08:29h | UTC
M-A: The incubation period distribution of coronavirus disease 2019 – “the mean incubation period of COVID-19 was likely to fall between 5.2 and 7.2 days, and the 95th percentile would be between 11 and 14.6 days”.
16 Jun, 2021 | 08:27h | UTC
A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
16 Jun, 2021 | 08:26h | UTCA long-term perspective on immunity to COVID – Nature
France recommends single dose of vaccine if previous Covid infection detected.
16 Jun, 2021 | 08:24h | UTCFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Related: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
M-A: Extracorporeal membrane oxygenation for COVID-19.
16 Jun, 2021 | 08:22h | UTC
WHO official: Delta variant ‘poised to take hold’ in Europe.
15 Jun, 2021 | 09:06h | UTCWHO official: Delta variant ‘poised to take hold’ in Europe – The Hill
[Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant.
15 Jun, 2021 | 09:09h | UTCNews Release: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Commentary on Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— UK Health Security Agency (@UKHSA) June 14, 2021
(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.
15 Jun, 2021 | 09:12h | UTCCommentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox
Commentary on Twitter (thread – click for more)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
SARS-CoV-2 Delta variant in Scotland: demographics, risk of hospital admission, and vaccine effectiveness – “Risk of COVID-19 hospital admission was approximately doubled in those with the Delta VOC when compared to the Alpha VOC”.
15 Jun, 2021 | 09:10h | UTCCommentaries: Delta may raise hospitalisation but vaccine still protects – UK Research and Innovation AND Expert reaction to Lancet research letter analysing data from Scotland on the Delta variant, looking at demographics, risk of hospital admission and vaccine effectiveness – Science Media Centre
Commentary on Twitter (thread – click for more)
Just published @TheLancet
The #DeltaVariant experience in Scotlandhttps://t.co/IfjDJnCAMC
1. #VaccinesWork ("AZ appeared less effective than Pfizer")
2. Younger, unvaccinated got the delta infections
3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant pic.twitter.com/cP8clu57Rd— Eric Topol (@EricTopol) June 14, 2021
Delta variant producing more severe illness, doctors in China say.
15 Jun, 2021 | 09:02h | UTCIn China’s latest outbreak, doctors say the infected get sicker, faster. – The New York Times (a few articles per month are free)
Delta variant causes more than 90% of new Covid cases in UK.
15 Jun, 2021 | 09:04h | UTCDelta variant causes more than 90% of new Covid cases in UK – The Guardian
Commentary on Twitter (thread – click for more)
⚠️90-96% of all #COVID19 in 🇬🇧 caused by #DeltaVariant.🧵
📍32% of all Delta cases visiting the hospital emergency room are at least 1 dose vaccinated
📍33% who are then hospitalized vaccinated
📍45% of all deaths got at least 1 shot—➡️ 29% got 2 shots.https://t.co/RViq5NiioQ pic.twitter.com/v2OYV2GM09
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
A new coronavirus variant (Delta) is on the rise. Here’s why experts are concerned.
15 Jun, 2021 | 09:03h | UTCA new coronavirus variant is on the rise. Here’s why experts are concerned – CNN
Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.
15 Jun, 2021 | 08:59h | UTCCommentaries: For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection – Hopkins Medicine AND Extra COVID Vaccine May Help Protect Transplant Patients – Associated Press
Commentary on Twitter
Our report about 3rd vaccine doses in transplant patients is published! "It is encouraging that antibody titers increased after the 3rd dose in 1/3 of patients who had negative antibody titers and in all patients who had low-positive antibody titers"https://t.co/6XElwyIdAa
— Dorry Segev (@Dorry_Segev) June 14, 2021
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
14 Jun, 2021 | 08:52h | UTCImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Commentaries on Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021
Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants.
14 Jun, 2021 | 08:53h | UTCBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Commentary on Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.
14 Jun, 2021 | 08:48h | UTCCommentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay
Commentary on Twitter
About 1 in every 3,000 children who got COVID ended up with MIS-C. MIS-C incidence among Black persons and Hispanic or Latino persons was approximately 9x higher, and incidence among Asian or Pacific Islander persons was approximately 3x higher https://t.co/JTEsvgvFcz
— Daniel Griffin MD PhD (@DanielGriffinMD) June 12, 2021
Children with symptomatic SARS-CoV-2 infection have similar viral loads and may be as contagious as symptomatic adults.
14 Jun, 2021 | 08:49h | UTCEditorial: Implications of SARS-CoV-2 Viral Load in Children: Getting Back to School and Normal
Commentary on Twitter (thread – click for more)
In a new study in @JAMAPediatrics, we compared symptoms and viral load in children and adults with SARS-CoV-2. Those with symptoms had higher virus loads than those without. Importantly, within these groups – viral load was the same in children and adults. https://t.co/UgaFzvMNlg pic.twitter.com/cjpt2yqQ3R
— Helen Chu (@HelenChuMD) June 11, 2021
Opinion | I Run the W.H.O., and I Know That Rich Countries Must Make a Choice.
14 Jun, 2021 | 08:44h | UTCI Run the W.H.O., and I Know That Rich Countries Must Make a Choice – The New York Times